Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE)
Background Randomized controlled trials (RCTs) demonstrated the advantages of an aerosol foam formulation of calcipotriol/betamethasone dipropionate (Cal/BD) in patients with psoriasis. In this review, we investigated whether such benefits could also be obtained in real-world clinical practice. Meth...
Main Authors: | Sascha Gerdes, Manuel Velasco, Jashin J. Wu, Mario Hubo, Karen A. Veverka |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-11-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2020.1717417 |
Similar Items
-
Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature
by: Pinter A, et al.
Published: (2018-10-01) -
Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis
by: Kim A. Papp, et al.
Published: (2022-10-01) -
Low incidence of hypercalcemia following combined calcipotriol hydrate/betamethasone dipropionate ointment treatment in Japanese patients with severe psoriasis vulgaris
by: Akimichi Morita, et al.
Published: (2018-07-01) -
Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris
by: C. Queille-Roussel, et al.
Published: (2019-08-01) -
Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment
by: Lidia Rudnicka, et al.
Published: (2021-11-01)